Jesper Pass

Title: Jesper Pass: Innovator in Antibody Research

Introduction

Jesper Pass is a notable inventor based in Alleroed, Denmark. He has made significant contributions to the field of antibody research, holding a total of 2 patents. His work focuses on developing innovative solutions for therapeutic applications.

Latest Patents

Jesper Pass's latest patents include groundbreaking inventions in the realm of antibodies. One of his patents is for "Antibodies that bind urokinase plasminogen activator." This invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. It also encompasses antibodies capable of binding uPA and reducing or inhibiting uPA activity. Furthermore, the invention outlines various therapeutic and pharmaceutical uses for such antibodies. Another significant patent is for "Anti-human interleukin-20 antibodies." This patent describes anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in multiple species, including humans. It also includes antigen-binding molecules and methods for producing these antibodies, which can be utilized in treating various autoimmune or inflammatory diseases.

Career Highlights

Jesper Pass is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk focuses on advancing research in antibody therapies, contributing to the development of innovative treatments for various diseases.

Collaborations

Jesper collaborates with esteemed colleagues such as Soeren Padkjaer and Gustav Roeder. Their combined expertise enhances the research and development efforts within their field.

Conclusion

Jesper Pass is a prominent inventor whose work in antibody research has the potential to impact therapeutic applications significantly. His patents reflect a commitment to advancing medical science and improving patient outcomes.